• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    JP Morgan resumed coverage on BioCryst Pharma with a new price target

    11/20/23 7:20:41 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCRX alert in real time by email
    JP Morgan resumed coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $10.00
    Get the next $BCRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCRX

    DatePrice TargetRatingAnalyst
    4/29/2025$20.00Overweight
    Cantor Fitzgerald
    2/25/2025$15.00Outperform
    Wedbush
    11/20/2023$10.00Overweight
    JP Morgan
    9/18/2023$9.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    8/4/2023$11.00Hold → Buy
    Jefferies
    7/13/2023$10.00Neutral → Buy
    BofA Securities
    2/22/2023$14.00Hold → Buy
    Needham
    11/2/2022$14.00 → $16.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $BCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sanders Machelle was granted 12,500 shares, increasing direct ownership by 45% to 40,242 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      6/16/25 4:22:22 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Milano Vincent was granted 12,500 shares, increasing direct ownership by 16% to 89,760 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      6/16/25 4:21:59 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Mckee Amy E was granted 12,500 shares, increasing direct ownership by 45% to 40,331 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      6/16/25 4:21:36 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care